125 related articles for article (PubMed ID: 24189498)
1. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation.
Hoppentocht M; Hagedoorn P; Frijlink HW; de Boer AH
Eur J Pharm Biopharm; 2014 Jan; 86(1):23-30. PubMed ID: 24189498
[TBL] [Abstract][Full Text] [Related]
2. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis.
Hickey AJ; Misra A; Fourie PB
J Pharm Sci; 2013 Nov; 102(11):3900-7. PubMed ID: 23963705
[TBL] [Abstract][Full Text] [Related]
3. Dry powder inhalable formulations for anti-tubercular therapy.
Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
[TBL] [Abstract][Full Text] [Related]
4. How can we bring high drug doses to the lung?
Claus S; Weiler C; Schiewe J; Friess W
Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
[TBL] [Abstract][Full Text] [Related]
5. Inhaled antibiotics to treat lung infection.
Cipolla D; Chan HK
Pharm Pat Anal; 2013 Sep; 2(5):647-63. PubMed ID: 24237172
[TBL] [Abstract][Full Text] [Related]
6. Antitubercular inhaled therapy: opportunities, progress and challenges.
Pandey R; Khuller GK
J Antimicrob Chemother; 2005 Apr; 55(4):430-5. PubMed ID: 15761077
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats.
Khadka P; Sinha S; Tucker IG; Dummer J; Hill PC; Katare R; Das SC
Eur J Pharm Biopharm; 2021 May; 162():1-11. PubMed ID: 33639255
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
Danckwerts MP; Ebrahim S; Pillay V
Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
[TBL] [Abstract][Full Text] [Related]
9. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.
Garcia-Contreras L; Fiegel J; Telko MJ; Elbert K; Hawi A; Thomas M; VerBerkmoes J; Germishuizen WA; Fourie PB; Hickey AJ; Edwards D
Antimicrob Agents Chemother; 2007 Aug; 51(8):2830-6. PubMed ID: 17517845
[TBL] [Abstract][Full Text] [Related]
10. [A case of multidrug-resistant pulmonary tuberculosis].
Tsurutani J; Sohda H; Oka M; Kohno S
Nihon Kokyuki Gakkai Zasshi; 2000 Aug; 38(8):594-8. PubMed ID: 11061084
[TBL] [Abstract][Full Text] [Related]
11. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
Mehta P; Bothiraja C; Kadam S; Pawar A
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder.
Chan JG; Tyne AS; Pang A; McLachlan AJ; Perera V; Chan JC; Britton WJ; Chan HK; Duke CC; Young PM; Traini D
Int J Antimicrob Agents; 2015 Mar; 45(3):319-23. PubMed ID: 25554469
[TBL] [Abstract][Full Text] [Related]
14. Single-use disposable dry powder inhalers for pulmonary drug delivery.
Friebel C; Steckel H
Expert Opin Drug Deliv; 2010 Dec; 7(12):1359-72. PubMed ID: 21080859
[TBL] [Abstract][Full Text] [Related]
15. Simple and scalable method for peptide inhalable powder production.
Schoubben A; Blasi P; Giovagnoli S; Ricci M; Rossi C
Eur J Pharm Sci; 2010 Jan; 39(1-3):53-8. PubMed ID: 19879945
[TBL] [Abstract][Full Text] [Related]
16. [Short-course chemotherapy for pulmonary tuberculosis. 2. Evaluation of short-course chemotherapy in experimental murine tuberculosis (author's transl)].
Oda T
Kekkaku; 1981 Jan; 56(1):17-21. PubMed ID: 7230589
[No Abstract] [Full Text] [Related]
17. Cationic, amphiphilic dextran nanomicellar clusters as an excipient for dry powder inhaler formulation.
Vadakkan MV; Binil Raj SS; Kartha CC; Vinod Kumar GS
Acta Biomater; 2015 Sep; 23():172-188. PubMed ID: 26013041
[TBL] [Abstract][Full Text] [Related]
18. [Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients].
Khodashova ML; Iuditskiĭ MV; Semenova OV
Probl Tuberk Bolezn Legk; 2004; (3):26-8. PubMed ID: 15338896
[TBL] [Abstract][Full Text] [Related]
19. [Drug therapy of tuberculosis in 1983].
Chaulet P
Bull Int Union Tuberc; 1983 Mar; 58(1):26-36. PubMed ID: 6616098
[No Abstract] [Full Text] [Related]
20. [Estimation of the possibilities of using unified chemotherapy regimens in new cases of pulmonary tuberculosis in old-age children and adolescents].
Gubkina MF; Ershova NG
Probl Tuberk Bolezn Legk; 2009; (1):33-6. PubMed ID: 19256010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
